On the front page of today’s New York Times, journalist Pam Belluck lays out the plight of a large set of extended families in Colombia who suffer from eFAD owing to the Paisa mutation in presenilin-1 (Lopera et al., 1997). Belluck traveled to Colombia this past January with ARF adviser Eric Reiman and Pierre Tariot of the Banner Alzheimer’s Institute in Phoenix, Arizona. With Francisco Lopera of Antioquia University School of Medicine, Medellín, and ARF Adviser Kenneth Kosik of the University of California, Santa Barbara, the Banner scientists are developing the Alzheimer’s Prevention Initiative (see ARF related news series; Banner Alzheimer’s Institute). The API aims at nothing less than jumpstarting an era of biomarker-supported prevention research with the help of these Colombian families and also with people in the U.S. who are at high imminent risk of AD due to their ApoE status and age. In a sign that prevention trials are shifting from “should do” to “will do,” other academic and industry groups are getting serious about planning them, as well (see upcoming ARF Webinar).—Gabrielle Strobel.

Comments

Make a Comment

To make a comment you must login or register.

Comments on this content

No Available Comments

Comments on Primary Papers for this Article

No Available Comments on Primary Papers for this Article

References

News Citations

  1. Phoenix: Vision of Shared Prevention Trials Lures Pharma to Table

Webinar Citations

  1. Treating Before Symptoms—ADCS Invites Ideas for Clinical Trials in Very Early AD

Paper Citations

  1. . Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA. 1997 Mar 12;277(10):793-9. PubMed.

External Citations

  1. front page of today’s New York Times
  2. Banner Alzheimer’s Institute

Further Reading

News

  1. Phoenix: Vision of Shared Prevention Trials Lures Pharma to Table